Jupiter Neurosciences, Inc. (JUNS)
NASDAQ: JUNS · Real-Time Price · USD
0.2100
-0.0700 (-25.00%)
At close: Jun 29, 2026, 4:00 PM EDT
0.2089
-0.0011 (-0.52%)
After-hours: Jun 29, 2026, 7:59 PM EDT
Jupiter Neurosciences Revenue
Jupiter Neurosciences had revenue of $18.65K in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $40.45K. In the year 2025, Jupiter Neurosciences had annual revenue of $21.80K.
Revenue (ttm)
$40.45K
Revenue Growth
n/a
P/S Ratio
223.84
Revenue / Employee
$8,090
Employees
5
Market Cap
9.12M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 21.80K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 233.28K | -404.76K | -63.44% |
| Dec 31, 2021 | 638.04K | -488.20K | -43.35% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bolt Biotherapeutics | 6.50M |
| Immuron | 4.99M |
| BioRestorative Therapies | 357.87K |
| Aprea Therapeutics | 123.30K |
| Aspire Biopharma Holdings | 34.56K |
| Ernexa Therapeutics | 1,000.00 |
JUNS News
- 3 days ago - Jupiter Neurosciences files to sell 16M shares of common stock for holders - TheFly
- 4 weeks ago - Jupiter Neurosciences commences patient enrollment in RESET trial - TheFly
- 4 weeks ago - Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease - GlobeNewsWire
- 4 weeks ago - D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering - Accesswire
- 5 weeks ago - Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering - GlobeNewsWire
- 5 weeks ago - Jupiter Neurosciences announces pricing of $2M registered direct offering - TheFly
- 5 weeks ago - Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering - GlobeNewsWire
- 5 weeks ago - Jupiter Neurosciences to acquire licensing rights to ALA-002 for $3.33M upfront - TheFly